ANZCTR - Registration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers

Trial registered on ANZCTR

Registration number

ACTRN12620000964910

Ethics application status

Approved

Date submitted

4/08/2020

Date registered

28/09/2020

Date last updated

6/05/2022

Date data sharing statement initially provided

28/09/2020

Date results information initially provided

6/05/2022

Type of registration

Prospectively registered

Titles & IDs

Public title

Cognitive Training in Children with Attention-Deficit/Hyperactivity Disorder

Scientific title

Cognitive Training in Children with Attention-Deficit/Hyperactivity Disorder: A Randomised Controlled Trial

Secondary ID [1]

None

Universal Trial Number (UTN)

U1111-1250-2620

Trial acronym

ATICA

Linked study record

None

Health condition

Health condition(s) or problem(s) studied:

Attention-Deficit/Hyperactivity Disorder (ADHD)

Condition category

Condition code

Mental Health

Other mental health disorders

Intervention/exposure

Study type

Interventional

Description of intervention(s) / exposure

The intervention training program is a gamed-based computerised training program, delivered on a tablet. In total, training sessions take 20 minutes to complete. Children will be required to complete five sessions per week for five weeks. The training program will be used in the child's home, and under the supervision of a parent or guardian.

The intervention targets four core attention and inhibitory control abilities: selective attention (i.e., trains the child to attend to relevant stimuli whilst filtering out distractions), sustained attention (i.e., the child develops the ability to maintain his/her attention on an object over a prolonged period of time), interference control (i.e., the child develops the ability to choose what stimuli to attend to and which to ignore) and response inhibition (i.e., trains the child to respond to target stimuli and withhold responses from non-target stimuli). Children may complete the activities in any order, but they must complete all activities during each session.

The intervention program has been designed to be adaptive to the skill of the child. Therefore, as children progress through the levels within each activity, the tasks become more difficult.

To enhance motivation, the game utilities child-friendly characters, and children are rewarded for successful completion of an activity.

Adherence to the intervention program will be assessed via a web portal, during regular contact with an unblinded member of the research team, and parents will complete a motivation log for each session.

Intervention code [1]

Treatment: Devices

Intervention code [2]

Behaviour

Comparator / control treatment

In order to control for generic training effects and to maintain blindness to group allocation, a commercially available active control program will be utilised. The active control program is also computerised, game-based and delivered on a tablet in the child's home under supervision of a parent or guardian. As with the intervention program, the active control program is a motivational, reward-based and adaptive program which will be played for 20 minutes per session. As in the intervention group, children will be required to complete 5 session a week for a period of 5 week.

Adherence to the active control program will be assessed during regular contact with an unblinded member of the research team, and parents will complete a motivation log for each session.

Control group

Active

Outcomes

Primary outcome [1]

The primary outcome is change in attention and response inhibition performance as measured by the T.O.V.A.® Attention Comparison Score (ACS).
The T.O.V.A.® ACS is a composite score consisting of the sum of three component scores: 1) reaction time (RT) mean Half-1 (highly infrequent targets), 2) RT variability total (both halves), and 3) d-prime Half-2 (highly frequent targets).

Timepoint [1]

Baseline, Post-intervention (5 weeks after commencement of intervention, primary timepoint) and 3 months post commencement of intervention.

Secondary outcome [1]

Primary outcome [4]: Interference control as measured by the Child Attention Network Task (ANT), a modified, child-friendly version of the flanker task.

Timepoint [1]

Baseline, Post-intervention (5 weeks after commencement of intervention, primary timepoint) and 3 months post commencement of intervention.

Secondary outcome [2]

Visuospatial working memory will be assessed using the Corsi Block Tapping Test.

Timepoint [2]

Baseline, Post-intervention (5 weeks after commencement of intervention) and 3 months post commencement of intervention.

Secondary outcome [3]

Auditory working memory will be assessed using the Digit Span test.

Timepoint [3]

Baseline, Post-intervention (5 weeks after commencement of intervention) and 3 months post commencement of intervention.

Secondary outcome [4]

Behavioural attention will be assessed using the Strengths and Weaknesses of ADHD-symptoms and Normal-behaviours questionnaire (SWAN).

Timepoint [4]

Baseline, Post-intervention (5 weeks after commencement of intervention) and 3 months post commencement of intervention.

Secondary outcome [5]

Executive functioning will be assessed using the Behaviour Rating Inventory of Executive Functions Second Edition.

Timepoint [5]

Baseline, Post-intervention (5 weeks after commencement of intervention),3 months post commencement of intervention,

Secondary outcome [6]

Impairment in everyday functioning will be assessed using the Impairment Rating Scale.

Timepoint [6]

Baseline, Post-intervention (5 weeks after commencement of intervention),3 months post commencement of intervention.

Secondary outcome [7]

Social impairment will be assessed using the Social Responsiveness Scale Second Edition.

Timepoint [7]

Baseline, Post-intervention (5 weeks after commencement of intervention),3 months post commencement of intervention.

Secondary outcome [8]

Sustained attention performance as measured by the T.O.V.A.® (response time variability and omission errors)

Timepoint [8]

i) between baseline (pre-intervention) and the immediate post-intervention time point;
ii) between baseline and the 3-month post-intervention time point.

Secondary outcome [9]

Inhibition as measured by the T.O.V.A (commission errors and anticipatory responses)

Timepoint [9]

i) between baseline (pre-intervention) and the immediate post-intervention time point;
ii) between baseline and the 3-month post-intervention time point.

Secondary outcome [10]

Selective attention as measured by the TEACh (Balloon Hunt and Hector Cancellation; mean targets located)

Timepoint [10]

i) between baseline (pre-intervention) and the immediate post-intervention time point;
ii) between baseline and the 3-month post-intervention time point.

Eligibility

Key inclusion criteria

- Is between the ages of 5 years and 8 years 11 months at the time of randomisation.
- Has a primary DSM-IV or DSM-V diagnosis of ADHD as determined and confirmed by a trained clinician.
- Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant’s behalf.
- Whose parents/guardians agree to not initiate any other nonpharmacological therapy or intervention for the purpose of treating their child’s inattention for the 5-week intervention phase of the study.
- Whose parents/guardians agree to keep a stable dose of ADHD medication (if the child is medicated) for at least 4 weeks prior to trial entry, and for the 5-week intervention phase of the study.

Minimum age

5 Years

Maximum age

9 Years

Sex

Both males and females

Can healthy volunteers participate?

Key exclusion criteria

- Is unable to comprehend or follow study instructions (English), including where uncorrected sensory or physical/motor impairments are present (as reported by the parent or observed by the investigator).
- Has a history of major trauma
- Has a diagnosed or borderline intellectual delay as defined as IQ<80 on the WISC-V/WPPSI-IV.
- Has a known monogenic cause for their ADHD diagnosis.
- Has comorbid diagnoses other than Autism Spectrum Disorder, with significant symptoms that, in the opinion of the investigator, may confound study data/assessments, i.e. oppositional defiant disorder, conduct disorder or severe mental health conditions (e.g. severe selective mutism). Participants with a learning disorder may participate provided the disorder does not impact their ability to take part in the trial.
- Have not previously participated in a study of a cognitive training program
- Do not have a sibling also enrolled in this study

Study design

Purpose of the study

Treatment

Allocation to intervention

Randomised controlled trial

Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)

A researcher not directly involved in the analysis of the study results will be responsible for the implementation of the allocation. Allocation will be concealed using central randomisation by a computer. The documentation pertaining to the randomisation will be securely stored and inaccessible to researchers undertaking recruitment and testing. Researchers conducting screening and assessments will be unaware of group allocation for the duration of the trial (including data analysis). Prior to the commencement of each assessment session participants will be explicitly instructed not to discuss the contents of their assigned program with the researcher. Group allocation details and randomisation codes will only be available once all data collected has been entered into the study database for every participant and the database has been finalised, except in the case of an emergency. For any participant for whom the study blind is broken, the date, time, participant ID and reason for unblinding must be documented. On completion of the follow-up assessments researchers will open a sealed opaque envelope which contains details of the condition that the participant was assigned to.

Methods used to generate the sequence in which subjects will be randomised (sequence generation)

Block randomisation (ratio 1:1, with blocks of 10) will be used to maintain balance between intervention arms. Computer-generated random numbers will be used to allocate participants. The randomisation will be stratified by medication status (i.e., takes medication for ADHD or does not take medication for ADHD).

Masking / blinding

Blinded (masking used)

Who is / are masked / blinded?

The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data

Intervention assignment

Parallel

Other design features

Phase

Not Applicable

Type of endpoint/s

Efficacy

Statistical methods / analysis

The primary endpoint, to demonstrate efficacy, is the Post-intervention assessment (5 weeks after commencement of intervention). The 3 month post commencement assessments are defined as secondary endpoint (may demonstrate additional effects after the primary endpoint). To address the multiple (four) primary outcomes, we will apply a statistical correction for multiplicity.

For all outcomes (primary and secondary), estimates and 95% CI’s for the mean scores for the intervention and control groups for each time point will be presented. Multivariate linear regression will be used to estimate the difference between arms (intervention vs control) in the change in outcome scores i) from baseline until post-intervention assessment at 5 weeks (immediate effect), and ii) from baseline until post-intervention assessment at 3 months (sustained effects). Point estimates, 95% CI’s and p-values for the hypothesis test with null hypothesis of no difference between arms will be provided. For both the immediate and sustained effects models, baseline outcome and age will be controlled for as covariates in the analysis.

An a priori power analysis was based on the probability of finding at least one true intervention effect across the four primary outcomes (disjunctive or minimal power). The effect size for the sample size calculation was based on two RCTs of cognitive training for children with ADHD which have reported small (Cohen’s d 0.28) to medium (eta squared 0.13) effect sizes. For a disjunctive power of 90%, assuming equal group sizes, a correlation of 0.2 between outcomes, and after applying a Bonferroni correction (alpha level of .0125), a total sample size of 104 is required to detect a medium effect for at least one of the four outcomes (ds = 0.5). This study will aim to recruit 52 participants per group to achieve adequate statistical power.

Exploratory analyses will be conducted to assess the potential effect of the following factors on training outcomes: sleep, intrinsic motivation, ADHD medication, adherence to assigned program and family functioning.

Recruitment

Recruitment status

Completed

Date of first participant enrolment

Anticipated

1/01/2021

Actual

11/03/2021

Date of last participant enrolment

Anticipated

Actual

20/09/2021

Date of last data collection

Anticipated

23/12/2021

Actual

7/01/2022

Sample size

Target

100

Accrual to date

Final

Recruitment in Australia

Recruitment state(s)

VIC

Recruitment postcode(s) [1]

3800 - Monash University

Funding & Sponsors

Funding source category [1]

Government body

Name [1]

Medical Research Future Fund (MRFF) - Australian Government Department of Health

Address [1]

414 La Trobe St
Melbourne VIC 3000

Country [1]

Australia

Funding source category [2]

Government body

Name [2]

Australian National Health and Medical Research Council Developmental grant (APP1135686)

Address [2]

16 Marcus Clarke St,
Canberra ACT 2601

Country [2]

Australia

Primary sponsor type

Individual

Name

Professor Mark Bellgrove

Address

Monash University, Wellington Rd, Clayton VIC 3800

Country

Australia

Secondary sponsor category [1]

Individual

Name [1]

Professor Kim Cornish

Address [1]

Monash University, Wellington Rd, Clayton VIC 3800

Country [1]

Australia

Ethics approval

Ethics application status

Approved

Ethics committee name [1]

Monash University Human Ethics Research Committee

Ethics committee address [1]

Building 3E, Room 111, Monash University Clayton Campus, Wellington Road, Clayton, VIC 3800

Ethics committee country [1]

Australia

Date submitted for ethics approval [1]

30/04/2020

Approval date [1]

23/06/2020

Ethics approval number [1]

24095

Summary

Brief summary

The primary objective of this study is to evaluate whether an adaptive cognitive control program is able to reduce attention difficulties in children with ADHD. It is expected that children with ADHD who complete the intervention training program will show greater improvements in selective attention, sustained attention, interference control and response inhibition compared to children with ADHD who complete a control program. We also expect that children with ADHD who complete the intervention program will demonstrate greater improvements in behavioural inattention, everyday functioning, working memory, executive functioning and social impairment compared to children with ADHD who complete a control program.

Trial website

Trial related presentations / publications

Public notes

Contacts

Principal investigator

Name

Dr Hannah Kirk

Address

Monash University, Wellington Rd, Clayton VIC 3800

Country

Australia

Phone

+61 3 990 50230

Fax

[email protected]

Contact person for public queries

Name

Dr Sally Richmond

Address

Monash University, Wellington Rd, Clayton VIC 3800

Country

Australia

Phone

+61 3 99053935

Fax

[email protected]

Contact person for scientific queries

Name

Prof Kim Cornish

Address

Monash University, Wellington Rd, Clayton VIC 3800

Country

Australia

Phone

+61 3 99020488

Fax

[email protected]

Data sharing statement

Will individual participant data (IPD) for this trial be available (including data dictionaries)?

Yes

What data in particular will be shared?

Anonymised participant level data underlying published results will be made available upon request.

When will data be available (start and end dates)?

From time of trial outcome submission for up to 20 years.

Available to whom?

Researchers who provide a methodologically sound proposal to verify results.

Available for what types of analyses?

To verify trial outcomes.

How or where can data be obtained?

Through contacting the Principal Investigator ([email protected])

What supporting documents are/will be available?

Doc. No.	Type	Citation	Link	Email	Other Details	Attachment
7661	Informed consent form					379584-(Uploaded-06-04-2022-10-42-04)-Study-related document.pdf

Results publications and other study-related documents

Documents added manually

No documents have been uploaded by study researchers.

Documents added automatically

Source	Title	Year of Publication	DOI
Embase	Digital cognitive training in children with attention-deficit/hyperactivity disorder: a study protocol of a randomised controlled trial.	2022	https://dx.doi.org/10.1136/bmjopen-2021-055385

N.B. These documents automatically identified may not have been verified by the study sponsor.

Trial Review

Documents added manually

Documents added automatically